

1       **INTERAGENCY COORDINATING COMMITTEE ON THE VALIDATION OF**  
2       **ALTERNATIVE METHODS (ICCVAM) TEST METHOD NOMINATION:**  
3       **THE NATIONAL TOXICOLOGY PROGRAM (NTP)**  
4       **TWO-YEAR RODENT BIOASSAY**  
5       **DRAFT ICCVAM RECOMMENDED PRIORITY**  
6

7       In October 2007, the NTP Interagency Center for the Evaluation of Alternative  
8       Toxicological Methods (NICEATM) received a nomination (Appendix 1) requesting that  
9       the Interagency Coordinating Committee on the Validation of Alternative Methods  
10      (ICCVAM) evaluate the current validation status of the NTP two-year rodent bioassay for  
11      differentiating human carcinogens from human noncarcinogens. Carcinogenicity studies  
12      (i.e., two-year bioassays) conducted at the National Toxicology Program (NTP) generally  
13      employ both sexes of rats (Fischer 344/N or Wistar Han) and mice (B6C3F1 hybrid), and  
14      generally include three dose levels of a test substance plus an untreated control using 50  
15      animals per sex per dose group (Chhabra et al. 2003, King-Herbert and Thayer 2006). In  
16      accordance with its established test method nomination process (ICCVAM 2003),  
17      ICCVAM considered this nomination in conjunction with currently available information  
18      on this test method's usefulness and limitations, and proposed that the evaluation of this  
19      test method be assigned a "low priority", pending consideration of comments received  
20      from the public and its scientific advisory board, the Scientific Advisory Committee on  
21      Alternative Toxicological Methods. The rationale for this decision follows.

22      As stated in the 11<sup>th</sup> Edition of the NTP Report on Carcinogens<sup>1</sup>, "*The strongest evidence*  
23      *for establishing a relationship between exposure to any given substance and cancer in*  
24      *humans comes from epidemiological studies—studies of the occurrence of a disease in a*  
25      *defined population and the factors that affect its occurrence (Bradford 1971).*  
26      *Epidemiological studies of human exposure and cancer are difficult (Rothman 1986).*  
27      *They must rely on natural, not experimental, human exposures and must therefore*  
28      *consider many factors that may affect cancer prevalence besides the exposure under*  
29      *study. One such factor is the latency period for cancer development. The exposure to a*

---

<sup>1</sup> Report on Carcinogens, 2004. Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Introduction.

30 carcinogen often occurs many years (sometimes 20 to 30 years or more) before the first  
31 sign of cancer appears.

32 Another valuable method for identifying substances as potential human carcinogens is  
33 the long-term animal bioassay. These studies provide accurate information about dose  
34 and duration of exposure and they are less affected than epidemiology studies by possible  
35 interaction of the test substance with other chemicals or modifying factors (Huff 1999). In  
36 these studies, the substance is given to one or (usually) two species of laboratory rodents  
37 over a range of doses for nearly the animals' entire lives. Experimental cancer research  
38 is based on the scientific assumption that substances causing cancer in animals will have  
39 similar effects in humans. It is not possible to predict with complete certainty from  
40 animal studies alone which substances will be carcinogenic in humans. However, known  
41 human carcinogens that have been tested adequately in laboratory animals also cause  
42 cancer in laboratory animals (Fung et al. 1995). In many cases, a substance first was  
43 found to cause cancer in animals and later confirmed to cause cancer in humans (Huff  
44 1993). How laboratory animals respond to substances, including developing cancer and  
45 other illnesses, does not always strictly correspond to how people will respond.  
46 Nevertheless, laboratory animal studies remain the best tool for detecting potential  
47 human health hazards of all kinds, including cancer (OTA 1981, Tomatis et al. 1997).”

48

49 The above information supports the basis for the current utility of the two-year bioassay,  
50 which is further supported by extensive literature. It is important to recognize that short-  
51 term studies are conducted when deemed appropriate on species-comparative  
52 pharmacokinetics, metabolism, and epigenetic and genetic mechanisms to extend and  
53 clarify the cancer bioassay findings. ICCVAM concluded that, in light of this  
54 information and ICCVAM priorities described in the recent NICEATM-ICCVAM 5-Year  
55 Plan<sup>2</sup> (ICCVAM 2008), any further evaluation of this assay should have a low priority at  
56 this time. However, while this represents the proposed current priority for this test  
57 method, ICCVAM and NICEATM recognize that future planning and priorities must be  
58 flexible in order to take advantage of opportunities resulting from advances in science  
59 and technology, development of new methods, and to respond to new testing needs.

---

<sup>2</sup> <http://iccvam.niehs.nih.gov/docs/5yearplan.htm>

60 **References**

- 61 Bradford HA. 1971. Principles of Medical Statistics. The Lancet Ltd, London.
- 62 Chhabra RS, Bucher JR, Wolfe M, Portier C. 2003. Toxicity characterization of  
63 environmental chemicals by the US National Toxicology Program: an overview. *Int J*  
64 *Hyg Environ Health* 206:437-45.
- 65 Fung VA, Barrett JC, Huff JE 1995. The Carcinogenesis Bioassay in Perspective:  
66 Application in Defining Human Cancer Hazards. *Environ Health Perspect* 103:680-683.
- 67 Huff JE. 1993. Chemicals and Cancer in Humans: First evidence in experimental  
68 animals. *Environ. Health Perspect* 100:201-210.
- 69 Huff JE. 1999. Value, validity, and historical development of carcinogenesis studies for  
70 predicting and confirming carcinogenic risks to humans. In: *Carcinogenicity Testing,*  
71 *Predicting, and Interpreting Chemical Effects.* K.T. Kitchin, ed. Marcel Dekker: New  
72 York. pp. 21-123.
- 73 ICCVAM. 2008. NICEATM-ICCVAM Five-Year Plan (2008-2012): A Plan to Advance  
74 Alternative Test Methods of High Scientific Quality to Protect and Advance the Health of  
75 People, Animals and the Environment. NIH Publication 2008: No. 08-6410. NIEHS,  
76 Research Triangle Park, NC.
- 77 King-Herbert A, Thayer K. 2006. NTP workshop: animal models for the NTP rodent  
78 cancer bioassay: stocks and strains--should we switch? *Toxicol Pathol* 34:802-805.
- 79 OTA. 1981. Assessment of Technologies for Determining Cancer Risks from the  
80 Environment. Office of Technology Assessment, U.S. Government Printing Office:  
81 Washington, DC.
- 82 Report on Carcinogens, 2004. Eleventh Edition; U.S. Department of Health and Human  
83 Services, Public Health Service, National Toxicology Program.
- 84 Rothman KJ. 1986. *Modern Epidemiology.* Little, Brown and Co., Boston.
- 85 Tomatis L, Huff J, Hertz-Picciotto I, Sandler D, Bucher J, Boffetta P, Axelson O, Blair  
86 A, Taylor J, Stayner L, and Barrett JC. 1997. Avoided and Avoidable Risks of Cancer.  
87 *Carcinogenesis* 18:97-105.